Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 237.26B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 14.62 |
| Forward PE | 15.10 |
| Dividend | 2.86 (3.04%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 2,093 |
| Average Volume | 5,270 |
| Open | 95.80 |
| Previous Close | 94.80 |
| Day's Range | 94.20 - 95.80 |
| 52-Week Range | 65.50 - 98.20 |
| Beta | 0.30 |
| RSI | 65.32 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Arbutus Biopharma Shares Fall 19% On European Patent Revocation
(RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents, EP2279254, after years of opposition pro...
Merck (MRK) Involved in European Patent Dispute Affecting Arbutus
Merck (MRK) Involved in European Patent Dispute Affecting Arbutus
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Is Merck Stock A Trap At $110?
Merck stock surged more than 10% in a month after management delivered a confidence shock on January 12th. They're now projecting that their next-generation drugs—treatments for cardiometabolic, respi...
See Which Of The Latest 13F Filers Holds MRK
At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 12/31/2025 reporting period, and noticed that Merck & Co Inc (Symbol: MRK) was held by 12 of these fund...
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks
The U.S. Food and Drug Administration (FDA) reportedly delayed reviews of several drugs selected for the Trump administration’s new fast-track approval program, after agency scientists raised concerns...
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed at $111.01 in the latest trading session, marking a +2.54% move from the prior day.
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.
Is Merck & Co Inc Gaining or Losing Market Support?
Merck & Co Inc's (NYSE: MRK) short interest as a percent of float has fallen 12.57% since its last report. According to exchange reported data, there are now 32.57 million shares sold short , which i...
Dow Analyst Moves: MRK
The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Merck is the #10 analyst pick. Merck also comes in above...
Merck (MRK) Eyes Major Acquisitions Amid Strategic Expansion
Merck (MRK) Eyes Major Acquisitions Amid Strategic Expansion
Merck signals appetite for multi-billion-dollar acquisitions
Merck (MRK) Raises Revenue Forecast for New Growth Drivers
Merck (MRK) Raises Revenue Forecast for New Growth Drivers
Merck & Co Inc at JPMorgan Healthcare Conference Transcript
Merck & Co Inc at JPMorgan Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s
Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by the mid-2030s, as it accelerates the launch of additional drugs...
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Rumors
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Rumors
Revolution Medicines declines to comment on M&A speculation at conference
Revolution Medicines (RVMD) declines to comment on Merck (MRK) M&A talks after $28B–$32B reports; RVMD stock dips post-surge.
Merck: FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new dru...
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metr...
3 Dividend Stocks to Hold for the Next 10 Years
Contrary to a common assumption, the tobacco industry isn't exactly imploding. There's still money to be made here.